Neurocrine initiated with Outperform at Bernstein on long runway of key drugs

Bernstein analyst Jeffrey Walch initiated coverage of Neurocrine (NBIX) with an Outperform rating and $221 price target The firm sees the company as one of the more promising investments within its initial coverage group of mid-cap biopharmaceutical companies, noting that Neurocrineb s two key medicines are both approved and have a long runway until loss-of-exclusivity, the analyst tells investors in a research note. Upside exists to Neurocrine’s current share price as the market gains more certainty on Crenessityb s future market share and osavampatorb’s Phase 3 trial reads-out positive, the firm added.Meet Samuel – Your Personal Investing ProphetStart a conversation with TipRanks’ trusted, data-backed investment intelligence

Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>